RSS-Feed abonnieren
DOI: 10.1055/s-0031-1280548
© Georg Thieme Verlag KG Stuttgart · New York
Aktuelles zur Thrombozytenaggregationshemmung
Update on anti-platelet therapyPublikationsverlauf
eingereicht: 18.2.2011
akzeptiert: 14.4.2011
Publikationsdatum:
31. Mai 2011 (online)

Zusammenfassung
Der ADP-Rezeptor (P2Y12)-Antagonist Clopidogrel hat sich in der Therapie des akuten Koronarsyndroms sowie nach koronarer Stent-Implantation zur dualen Thrombozytenaggregationshemmung neben Aspirin bewährt. Vor allem aufgrund der Metabolisierung in die aktive Form sowie seines irreversiblen Effektes hat Clopidogrel allerdings Nachteile, die seine Effektivität in der Reduktion klinischer Ereignisse beeinflussen könnten. Zwei Neuentwicklungen zur Thrombozytenaggregationshemmung bei akutem Koronarsyndrom könnten anwendungsrelevant werden. Der irreversible ADP-Rezeptor-Antagonist Prasugrel führt zu einer stärkeren Thrombozytenaggregationshemmung als Clopidogrel und zeigte in der TRITON-Studie weniger ischämische, aber mehr Blutungskomplikationen. Der ohne Metabolisierung wirksame, reversible ADP-Rezeptorantagonist Ticagrelor ist ebenfalls potenter als Clopidogrel in der Thrombozytenaggregationshemmung. Ticagrelor zeigte in der PLATO-Studie eine Reduktion ischämischer Ereignisse bei insgesamt nicht mehr schweren Blutungskomplikationen im Vergleich zu Clopidogrel, und führte außerdem zu einer Reduktion der Gesamtmortalität. Diese Übersichtsarbeit stellt bisherige Daten zu den neuen Substanzen zusammen und leitet mögliche Konsequenzen für die klinische Praxis ab.
Abstract
Use of the ADP (P2Y12)-receptor antagonist clopidogrel is a cornerstone of dual platelet inhibition in acute coronary syndromes and following stent implantation. Because of the metabolization into its active form and the irreversible inhibition of the ADP receptor there are disadvantages to clopidogrel which could limit its efficacy in reducing clinical events. This is particularly problematic in so-called poor responders with reduced metabolizing activity and hence reduced platelet inhibition. Two novel drugs for platelet inhibition in acute coronary syndrome could become relevant in clinical practice. The irreversible ADP-receptor antagonist prasugrel led to stronger platelet inhibition, fewer ischemic events but more bleeding complications compared to clopidogrel in the TRITON-TIMI-38 trial. The reversibly binding, direct-acting ADP-receptor antagonist ticagrelor, which is effective without metabolization, is also superior over clopidogrel in reducing platelet aggregation and decreased the number of ischemic events in the PLATO-trial. However, it did not increase the rate of overall major bleeding and was shown to reduce total mortality. This review article summarizes current data on novel platelet inhibitors and delineates their potential influence on clinical practice.
Schlüsselwörter
Thrombozytenaggregationshemmung - akutes Koronarsyndrom - perkutane Koronarintervention (PCI) - Ticagrelor - Prasugrel - Clopidogrel - Myokardinfarkt - Stentthrombose
Keywords
platelet inhibition - acute coronary syndrome - PCI - ticagrelor - prasugrel - clopidogrel - myocardial infarction - stent thrombosis
Literatur
- 1
Becker R C, Moliterno D J, Jennings L K. et al .
Safety and tolerability
of SCH 530 348 in patients undergoing non-urgent percutaneous
coronary intervention: a randomised, double-blind, placebo-controlled
phase II study.
Lancet.
2009;
373
919-928
MissingFormLabel
- 2
Bellemain-Appaix A, Brieger D, Beygui F. et al .
New P2Y12 Inhibitors Versus Clopidogrel
in Percutaneous Coronary Intervention: A Meta-Analysis.
J
Am Coll Cardiol.
2010;
56
1542-1551
MissingFormLabel
- 3
Bhatt D L, Lincoff A M, Gibson C M. et al .
Intravenous platelet blockade
with cangrelor during PCI.
N Engl J Med.
2009;
361
2330-2341
MissingFormLabel
- 4
Brandt J T, Close S L, Iturria S J. et al .
Common polymorphisms of
CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic
response to clopidogrel but not prasugrel.
J Thromb Haemost.
2007;
5
2429-2436
MissingFormLabel
- 5
Cannon C P, Harrington R A, James S. et al .
Comparison of ticagrelor with clopidogrel
in patients with a planned invasive strategy for acute coronary
syndromes (PLATO): a randomised double-blind study.
Lancet.
2010;
375
283-293
MissingFormLabel
- 6
Davi G, Patrono C.
Platelet activation and
atherothrombosis.
N Engl J Med.
2007;
357
2482-2494
MissingFormLabel
- 7
Gensch C, Hoppe U, Bohm M, Laufs U.
Late-breaking clinical trials presented
at the American Heart Association Congress in Chicago 2010.
Clin Res
Cardiol.
2010;
100
1-9
MissingFormLabel
- 8
Goto S, Ogawa H, Takeuchi M, Flather M D, Bhatt D L.
Double-blind, placebo-controlled Phase II
studies of the protease-activated receptor 1 antagonist E5555 (atopaxar)
in Japanese patients with acute coronary syndrome or high-risk coronary
artery disease.
Eur Heart J.
2010;
31
2601-2613
MissingFormLabel
- 9
Greenbaum A B, Grines C L, Bittl J A. et al .
Initial experience with
an intravenous P2Y12 platelet receptor antagonist in patients undergoing
percutaneous coronary intervention: results from a 2-part, phase
II, multicenter, randomized, placebo- and active-controlled trial.
Am Heart J.
2006;
151
689 e681-689 e610
MissingFormLabel
- 10
Gurbel P A, Bliden K P, Butler K. et al .
Response to ticagrelor in clopidogrel nonresponders
and responders and effect of switching therapies: the RESPOND study.
Circulation.
2010;
121
1188-1199
MissingFormLabel
- 11
Gurbel P A, Bliden K P, Butler K. et al .
Randomized double-blind assessment of the
ONSET and OFFSET of the antiplatelet effects of ticagrelor versus
clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET
study.
Circulation.
2009;
120
2577-2585
MissingFormLabel
- 12
Held C, Asenblad N, Bassand J P. et al .
Ticagrelor Versus Clopidogrel in Patients
With Acute Coronary Syndromes Undergoing Coronary Artery Bypass
Surgery: Results From the PLATO (Platelet Inhibition and Patient Outcomes)
Trial.
J Am Coll Cardiol.
2010;
DOI: 10.1016/j.jacc.2010.10.029
j.jacc.2010.2010.2029
MissingFormLabel
- 13
Ho P M, Maddox T M, Wang L. et al .
Risk of adverse outcomes associated with
concomitant use of clopidogrel and proton pump inhibitors following
acute coronary syndrome.
JAMA.
2009;
301
937-944
MissingFormLabel
- 14
Iyengar S, Rabbani L E.
Beyond platelet
inhibition: potential pleiotropic effects of ADP-receptor antagonists.
J Thromb Thrombolysis.
2009;
27
300-306
MissingFormLabel
- 15
James S, Angiolillo D J, Cornel J H. et al .
Ticagrelor vs. clopidogrel
in patients with acute coronary syndromes and diabetes: a substudy
from the PLATelet inhibition and patient Outcomes (PLATO) trial.
European Heart Journal.
2010;
31
3006-3016
MissingFormLabel
- 16
James S, Budaj A, Aylward P. et
al .
Ticagrelor versus clopidogrel in acute coronary
syndromes in relation to renal function: results from the platelet
inhibition and patient outcomes (PLATO) trial.
Circulation.
2010;
122
1056-1067
MissingFormLabel
- 17
James S, Roe M T, Cannon C P. et al .
Ticagrelor versus clopidogrel in patients
with Acute Coronary Syndrom intended for a non-invasive management
in the PLATO trial.
European Heart Journal.
2010;
31
1-296
MissingFormLabel
- 18
Leonardi S, Rao S V, Harrington R A. et al .
Rationale and design of
the randomized, double-blind trial testing INtraveNous and Oral
administration of elinogrel, a selective and reversible P2Y(12)-receptor
inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy
in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).
Am Heart J.
2010;
160
65-72
MissingFormLabel
- 19
Mega J L, Close S L, Wiviott S D. et al .
Cytochrome p-450 polymorphisms and
response to clopidogrel.
N Engl J Med.
2009;
360
354-362
MissingFormLabel
- 20
Mega J L, Close S L, Wiviott S D. et al .
Cytochrome P450 genetic
polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic,
and clinical outcomes.
Circulation.
2009;
119
2553-2560
MissingFormLabel
- 21
Mega J L, Close S L, Wiviott S D. et al .
Genetic variants in ABCB1
and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and
prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Lancet.
2010;
376
1312-1319
MissingFormLabel
- 22
Mehta S R, Cannon C P, Fox K A. et al .
Routine vs selective invasive
strategies in patients with acute coronary syndromes: a collaborative
meta-analysis of randomized trials.
JAMA.
2005;
293
2908-2917
MissingFormLabel
- 23
Mehta S R, Tanguay J F, Eikelboom J W. et al .
Double-dose versus standard-dose
clopidogrel and high-dose versus low-dose aspirin in individuals undergoing
percutaneous coronary intervention for acute coronary syndromes
(CURRENT-OASIS 7): a randomised factorial trial.
Lancet.
2010;
376
1233-1243
MissingFormLabel
- 24
Mehta S R, Yusuf S, Peters R J. et al .
Effects of pretreatment with clopidogrel
and aspirin followed by long-term therapy in patients undergoing percutaneous
coronary intervention: the PCI-CURE study.
Lancet.
2001;
358
527-533
MissingFormLabel
- 25
Montalescot G, Wiviott S D, Braunwald E. et al .
Prasugrel compared with clopidogrel in
patients undergoing percutaneous coronary intervention for ST-elevation
myocardial infarction (TRITON-TIMI 38): double-blind, randomised
controlled trial.
Lancet.
2009;
373
723-731
MissingFormLabel
- 26
Nergiz-Unal R, Cosemans J M, Feijge M A. et al .
Stabilizing role of platelet P2Y(12)
receptors in shear-dependent thrombus formation on ruptured plaques.
PLoS ONE.
2010;
5
e10130
MissingFormLabel
- 27
Patil S B, Jackman L E, Francis S E. et al .
Ticagrelor effectively and
reversibly blocks murine platelet P2Y12-mediated thrombosis and
demonstrates a requirement for sustained P2Y12 inhibition to prevent
subsequent neointima.
Arterioscler Thromb Vasc Biol.
2010;
30
2385-2391
MissingFormLabel
- 28
Patti G, Colonna G, Pasceri V. et
al .
Randomized trial of high loading dose of clopidogrel
for reduction of periprocedural myocardial infarction in patients
undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet
therapy for Reduction of MYocardial Damage during Angioplasty) study.
Circulation.
2005;
111
2099-2106
MissingFormLabel
- 29 PressRelease .European
Commission approves Efient® (Prasugrel). http://www.daiichi-sankyo.eu/site_eu/?node_id=27002009 accessed January 3, 2011
MissingFormLabel
- 30 PressRelease .Prasugrel
Receives Unanimous Approval Recommendation from FDA Advisory Committee. http://newsroomlilly.com/releasedetailcfm?releaseid=3633922009 accessed January 3, 2011
MissingFormLabel
- 31 PressRelease .AstraZeneca
receives complete response letter from US FDA for BRILINTA (ticagrelor
tablets). http://www.astrazeneca.com/Media/Press-releases/Article/20101217AstraZeneca-receives-complete-response-letter-from-FDA2010 accessed Dec 19, 2010
MissingFormLabel
- 32
Price M J, Berger P B, Teirstein P S. et al .
Standard- vs high-dose clopidogrel based
on platelet function testing after percutaneous coronary intervention:
the GRAVITAS randomized trial.
JAMA.
2011;
305
1097-1105
MissingFormLabel
- 33
Schirmer S H, van der Laan A M, Böhm M, Mahfoud F.
Hotlines
and clinical trial updates presented at the European Society of
Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT,
SYNTAX, TRITON and more.
Clin Res Cardiol.
2009;
98
691-699
MissingFormLabel
- 34
Schneider D J.
Mechanisms Potentially Contributing to the Reduction in Mortality
Associated With Ticagrelor Therapy.
J Am Coll Cardiol.
2010 ;
DOI: 10.1016/j.jacc.2010.1011.1016
MissingFormLabel
- 35
Schomig A.
Ticagrelor – Is There Need for a New Player in the
Antiplatelet-Therapy Field?.
N Engl J Med.
2009;
361
1108-1111
MissingFormLabel
- 36
Serebruany V L.
Paradoxical excess mortality in the PLATO trial should be independently
verified.
Thromb Haemost.
2011;
105
752-759
MissingFormLabel
- 37
Sofi F, Marcucci R, Gori A M. et al .
Clopidogrel non-responsiveness and risk
of cardiovascular morbidity. An updated meta-analysis.
Thromb Haemost.
2010;
103
841-848
MissingFormLabel
- 38
Steg P G, James S, Harrington R A. et al .
Ticagrelor Versus Clopidogrel in Patients
With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion
With Primary Percutaneous Coronary Intervention: A Platelet Inhibition
and Patient Outcomes (PLATO) Trial Subgroup Analysis.
Circulation.
2010;
122
2131-2141
MissingFormLabel
- 39
Wallentin L.
P2Y12 inhibitors: differences in properties and mechanisms of
action and potential consequences for clinical use.
European Heart
Journal.
2009;
30
1964-1977
MissingFormLabel
- 40
Wallentin L, Becker R C, Budaj A. et al .
Ticagrelor versus Clopidogrel in Patients
with Acute Coronary Syndromes.
N Engl J Med.
2009;
361
1045-1057
MissingFormLabel
- 41
Wallentin L, James S, Storey R F. et al .
Effect of CYP2C19 and ABCB1 single nucleotide
polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel
for acute coronary syndromes: a genetic substudy of the PLATO trial.
Lancet.
2010;
376
1320-1328
MissingFormLabel
- 42
Wallentin L, Varenhorst C, James S. et al .
Prasugrel achieves greater and faster P2Y12receptor-mediated
platelet inhibition than clopidogrel due to more efficient generation
of its active metabolite in aspirin-treated patients with coronary
artery disease.
Eur Heart J.
2008;
29
21-30
MissingFormLabel
- 43
Wijns W, Kolh P, Danchin N. et
al .
Guidelines on myocardial revascularization: The
Task Force on Myocardial Revascularization of the European Society
of Cardiology (ESC) and the European Association for Cardio-Thoracic
Surgery (EACTS).
Eur Heart J.
2010;
31
2501-2555
MissingFormLabel
- 44
Wiviott S D, Braunwald E, McCabe C H. et al .
Intensive oral antiplatelet therapy for
reduction of ischaemic events including stent thrombosis in patients
with acute coronary syndromes treated with percutaneous coronary
intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis
of a randomised trial.
Lancet.
2008;
371
1353-1363
MissingFormLabel
- 45
Wiviott S D, Braunwald E, McCabe C H. et al .
Prasugrel versus clopidogrel in patients
with acute coronary syndromes.
N Engl J Med.
2007;
357
2001-2015
MissingFormLabel
- 46
Yusuf S, Zhao F, Mehta S R. et al .
Effects of clopidogrel in addition to aspirin
in patients with acute coronary syndromes without ST-segment elevation.
N Engl J Med.
2001;
345
494-502
MissingFormLabel
Dr. Dr. med. Stephan H. Schirmer
Klinik für Innere Medizin III
Universitätsklinikum
des Saarlandes
Kirrberger Straße
66421 Homburg/Saar
Telefon: 06841/16-21333
Fax: 06841/16-23434
eMail: Stephan.Schirmer@uks.eu